Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia

[1]  J. Taub,et al.  Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia , 2019, Clinical Cancer Research.

[2]  K. Rottner,et al.  The Small GTPase Rac1 Increases Cell Surface Stiffness and Enhances 3D Migration Into Extracellular Matrices , 2019, Scientific reports.

[3]  L. Drew,et al.  BCL2 blockade overcomes MCL1 resistance in multiple myeloma , 2019, Leukemia.

[4]  F. Colland,et al.  Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia , 2018, Leukemia.

[5]  J. Thiery,et al.  Actin Cytoskeleton Remodeling Drives Breast Cancer Cell Escape from Natural Killer-Mediated Cytotoxicity. , 2018, Cancer research.

[6]  A. Vincent-Salomon,et al.  Coronin 1C promotes triple-negative breast cancer invasiveness through regulation of MT1-MMP traffic and invadopodia function , 2018, Oncogene.

[7]  Wei Li,et al.  Profilin 1 induces drug resistance through Beclin1 complex‐mediated autophagy in multiple myeloma , 2018, Cancer science.

[8]  D. Gomez,et al.  Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics. , 2018, Critical reviews in oncology/hematology.

[9]  F. Prósper,et al.  Deregulation of linc-PINT in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells , 2018, Oncotarget.

[10]  Markus Sauer,et al.  Cyanine Conformational Restraint in the Far-Red Range. , 2017, Journal of the American Chemical Society.

[11]  H. Kantarjian,et al.  FLT3 inhibition in acute myeloid leukaemia. , 2017, The Lancet. Oncology.

[12]  A. Luttun,et al.  A new strategy to measure intercellular adhesion forces in mature cell-cell contacts , 2017, Scientific Reports.

[13]  T. Thanabalu,et al.  WIP promotes in-vitro invasion ability, anchorage independent growth and EMT progression of A549 lung adenocarcinoma cells by regulating RhoA levels. , 2017, Biochemical and biophysical research communications.

[14]  A. Gingras,et al.  Plk4 Promotes Cancer Invasion and Metastasis through Arp2/3 Complex Regulation of the Actin Cytoskeleton. , 2017, Cancer research.

[15]  M. Kyba,et al.  MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome. , 2016, Cancer cell.

[16]  Hong Wang,et al.  Rac1b enhances cell survival through activation of the JNK2/c-JUN/Cyclin-D1 and AKT2/MCL1 pathways , 2016, Oncotarget.

[17]  Arthur Zimek,et al.  A Framework for Clustering Uncertain Data , 2015, Proc. VLDB Endow..

[18]  Yung Chang Hsu,et al.  Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification , 2015, Scientific Reports.

[19]  E. Hirsch,et al.  Crossroads of PI3K and Rac pathways , 2015, Small GTPases.

[20]  Doron Lancet,et al.  PathCards: multi-source consolidation of human biological pathways , 2015, Database J. Biol. Databases Curation.

[21]  H. Martin,et al.  Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. , 2014, Cell reports.

[22]  Shelly R. Peyton,et al.  Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening. , 2014, Biomaterials.

[23]  Silviya Zustiak,et al.  Multiwell stiffness assay for the study of cell responsiveness to cytotoxic drugs , 2014, Biotechnology and bioengineering.

[24]  K. Burridge,et al.  The on-off relationship of Rho and Rac during integrin-mediated adhesion and cell migration , 2014, Small GTPases.

[25]  M. Sauer,et al.  rapidSTORM: accurate, fast open-source software for localization microscopy , 2012, Nature Methods.

[26]  M. Levis,et al.  Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. , 2012, Blood.

[27]  James K Gimzewski,et al.  Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[28]  M. Desouza,et al.  The actin cytoskeleton as a sensor and mediator of apoptosis , 2012, Bioarchitecture.

[29]  Andrew Kasarskis,et al.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia , 2012, Nature.

[30]  D. King,et al.  Arp2/3 complex is bound and activated by two WASP proteins , 2011, Proceedings of the National Academy of Sciences.

[31]  B. Goh,et al.  The small GTPase Rac1 is a novel binding partner of Bcl-2 and stabilizes its antiapoptotic activity. , 2011, Blood.

[32]  Daniel K Treiber,et al.  Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. , 2010, Chemistry & biology.

[33]  Daniel A. Fletcher,et al.  Cell mechanics and the cytoskeleton , 2010, Nature.

[34]  B. Goh,et al.  ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside , 2009, Journal of hematology & oncology.

[35]  Charles P. Lin,et al.  RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. , 2009, Blood.

[36]  Tomaso Zambelli,et al.  FluidFM: combining atomic force microscopy and nanofluidics in a universal liquid delivery system for single cell applications and beyond. , 2009, Nano letters.

[37]  C. Der,et al.  Specificity and Mechanism of Action of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases* , 2007, Journal of Biological Chemistry.

[38]  K. Wood,et al.  Differential regulation of WASP and N-WASP by Cdc42, Rac1, Nck, and PI(4,5)P2. , 2007, Biochemistry.

[39]  D. Yamazaki,et al.  Effect of WAVE2 phosphorylation on activation of the Arp2/3 complex. , 2006, Journal of biochemistry.

[40]  E. Estey,et al.  Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. , 2006, Blood.

[41]  H. Kantarjian,et al.  Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. , 2004, Blood.

[42]  T. Naoe,et al.  Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. , 2003, Blood.

[43]  W. Hiddemann,et al.  Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  L. Blanchoin,et al.  Phosphorylation of the WASP-VCA domain increases its affinity for the Arp2/3 complex and enhances actin polymerization by WASP. , 2003, Molecular cell.

[45]  Doriano Fabbro,et al.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.

[46]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[47]  T. Takenawa,et al.  WASP and WAVE family proteins: key molecules for rapid rearrangement of cortical actin filaments and cell movement. , 2001, Journal of cell science.

[48]  S. Zigmond,et al.  Profilin Enhances Cdc42-Induced Nucleation of Actin Polymerization , 2000, The Journal of cell biology.

[49]  L. Van Aelst,et al.  Rho GTPases and signaling networks. , 1997, Genes & development.

[50]  P. Janmey,et al.  Effect of ATP on actin filament stiffness , 1990, Nature.

[51]  W. Kabsch,et al.  Atomic model of the actin filament , 1990, Nature.

[52]  M. Levis.  Quizartinib in acute myeloid leukemia. , 2013, Clinical advances in hematology & oncology : H&O.